期刊文献+

不同转移潜能肝癌细胞株中CD标志物的表达差异及意义 被引量:2

Expression and significance of CD markers in the hepatocellular carcinoma cell lines with different metastatic potential
暂未订购
导出
摘要 目的探讨不同转移潜能的肝癌细胞株中几种CD标记物的表达差异及其意义,为进一步利用CD分子标志物分离多潜能肝癌干细胞奠定基础。方法常规培养三种不同转移潜能的肝癌细胞株HepG2、MHCC-97H、SK-HEP-1,胰酶消化获得单细胞悬液后,经流式抗体染色,通过流式细胞仪分析三种肝癌细胞株中CD133、CD90、CD44、CD34、CD24的表达差异及意义。结果 CD133+细胞在HepG2细胞株仅占0.1%,而在MHCC-97H、SK-HEP-1细胞中表达也较低;CD90+、CD44+、CD90+CD44+表达水平随细胞转移潜能的增加呈递增趋势(P<0.05)。CD44+CD24+在HepG2、MHCC-97H、SK-HEP-1细胞中的阳性表达率分别为0.05%、10.3%和0.3%(P<0.05);三者中均无CD34+和CD133+CD90+细胞表达。结论 CD90和CD44与肝癌细胞的转移潜能有一定的相关性,可能成为潜在的肝癌肿瘤干细胞标记物。 Objective To evaluate the expression of several CD cell markers and investigate their significance in hepatocellular carcinoma cell lines with different metastatic potential. Methods Three human hepatocellular cell lines,HepG2,MHCC-97H and SK-HEP-1 were cultivated by routine method.Single cell suspension was achieved by digestion with trypsin.After CD133,CD90,CD44, CD34 and CD24 antibody labeling,cells were analyzed by flow cytometry. Results CD133+ cells represented only a very small subpopulation in three hepatocellular carcinoma cell lines(0.1%~0.4%).In addition,CD90+,CD44+ and CD90+CD44+cells were detected in the three cell lines and the percentage increased with the development of metastatic potential(P﹤0.05).The expression rates of CD44+CD24+ cells in HepG2,MHCC-97H and SK-HEP-1 were 0.05%,10.3% and 0.3%,respectively(P﹤0.05).Furthermore,no CD34+ or CD133+CD90+ expression was observed in the three cell lines. Conclusion CD90 and CD44 are significantly correlated with the metastatic potential of hepatocellular carcinoma cells and may be prospective markers for hepatocellular carcinoma stem cells.
出处 《胃肠病学和肝病学杂志》 CAS 2012年第3期221-223,共3页 Chinese Journal of Gastroenterology and Hepatology
基金 国家自然科学基金资助项目(30873038 30972759)
关键词 肝细胞癌 CD133 CD90 CD44 CD34 CD24 Hepatocellular carcinoma CD133 CD90 CD44 CD34 CD24
  • 相关文献

参考文献11

  • 1Farazi PA,DePinho RA.Hepatocellular carcinoma pathogenesis:fromgenes to environment[J].Nat Rev Cancer,2006,6(9):674-687.
  • 2O’Brien CA,Pollett A,Gallinger S,et al.A human colon cancer cellcapable of initiating tumour growth in immunodeficient mice[J].Na-ture,2007,445(7123):106-110.
  • 3Singh SK,Hawkins C,Clarke ID,et al.Identification of human braintumour initiating cells[J].Nature,2004,432(7015):396-401.
  • 4Ricci-Vitiani L,Lombardi DG,Pilozzi E,et al.Identification and ex-pansion of human colon-cancer-initiating cells[J].Nature,2007,445(7123):111-115.
  • 5La'zaro CA,Croager EJ,Mitchell C,et al.Establishment,character-ization,and long-term maintenance of cultures of human fetal hepato-cytes[J].Hepatology,2003,38(5):1095-1106.
  • 6Al-Hajj M,Wicha MS,Benito-Hernandez A,et al.Prospective identi-fication of tumorigenic breast cancer cells[J].Proc Natl Acad Sci U SA,2003,100(7):3983-3988.
  • 7Prince ME,Sivanandan R,Kaczorowski A,et al.Identification of asubpopulation of cells with cancer stem cell properties in head and necksquamous cell carcinoma[J].Proc Natl Acad Sci U S A,2007,104(3):973-978.
  • 8Li C,Heidt DG,Dalerba P,et al.Identification of pancreatic cancerstem cells[J].Cancer Res,2007,67(3):1030-1037.
  • 9Suetsugu A,Nagaki M,Aoki H,et al.Characterization of CD133+hepatocellular carcinoma cells as cancer stem/progenitor cells[J].Biochem Biophys Res Commun,2006,351(4):820-824.
  • 10Yin S,Li J,Hu C,et al.CD133positive hepatocellular carcinomacells possess high capacity for tumorigenicity[J].Int J Cancer,2007,120(7):1444-1450.

同被引文献12

  • 1许东晖,王胜,金晶,梅雪婷,许实波.姜黄素的药理作用研究进展[J].中草药,2005,36(11):1737-1740. 被引量:87
  • 2Park K, Lee MY, Kim KS, et al. Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate [J]. Biomaterials, 2010, 31 (19) : 5258-5265.
  • 3Naor D, Wallach-Dayan SB, Zahalka MA, et al. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination [J]. Semin Cancer Biol, 2008, 18 (4): 260-267.
  • 4Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours [J]. Eur J Cancer, 2010, 46 (7) : 1271-1277.
  • 5Surace C, Arpicco S, Dufa:-Wojcicki A, et al. Lipoplexes targeting the CD44 hyaluronic acid receptor for efficient transfection of breast cancer cells [J]. Mol Pharm, 2009, 6(4): 1062-1073.
  • 6Eliaz RE, Szoka FC Jr. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells EJ]. CancerRes, 2001, 61 (6) : 2592-2601.
  • 7Taetz S, Bochot A, Surace C, et al. Hyaluronic acid-modified DOTAP/DOPE liposomes for the targeted delivery of anti- telomerase siRNA to CD44-expressing lung cancer cells [J]. Oligonucleotides, 2009, 19 (2): 103-116.
  • 8Oh EJ, Park K, Kim KS, et al. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic :d derivatives [J]. J Controlled Release, 2010, 141 (1) : 2-12.
  • 9Wojcicki AD, Hillaireau H, Nascimento TL, et al. Hyaluronic acid-bearing lipoplexes: Physico-chemical characterization and in vitro targeting of the CD44 receptor [J]. J Controlled Release, 2012, 162 (3) : 545-552.
  • 10李彧,杨丽霞,李亚东,刘铜华,王继峰.姜黄素抗纤维化作用研究进展[J].北京中医药大学学报,2008,31(6):408-411. 被引量:12

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部